Home › Trial NCT02204033
Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody (hMAb) BIWA 4 in Patients With Head and Neck Cancer
- Trial IDNCT02204033
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorBoehringer Ingelheim
- Enrollment33
- Start date1999-03
- ConditionsHead and Neck Neoplasms
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.